NASDAQ:MGTX - MeiraGTx Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $33.00
  • Forecasted Upside: 126.65 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$14.56
▲ +0.66 (4.75%)
1 month | 3 months | 12 months
Get New MeiraGTx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MGTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MGTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$33.00
▲ +126.65% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for MeiraGTx in the last 3 months. The average price target is $33.00, with a high forecast of $45.00 and a low forecast of $20.00. The average price target represents a 126.65% upside from the last price of $14.56.
Buy
The current consensus among 4 polled investment analysts is to buy stock in MeiraGTx. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/12/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/11/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/10/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/3/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/22/2020Royal Bank of CanadaInitiated CoverageOutperform$27.00High
i
9/15/2020Bank of AmericaInitiated CoverageBuy$20.00High
i
8/16/2020Chardan CapitalReiterated RatingBuy$45.00Medium
i
Rating by Gbola Amusa at Chardan Capital
7/17/2020Piper SandlerReiterated RatingBuy$40.00High
i
Rating by Tyler Van Buren at Piper Sandler
7/17/2020Chardan CapitalReiterated RatingBuy$45.00High
i
Rating by Gbola Amusa at Chardan Capital
5/31/2020Chardan CapitalReiterated RatingBuy$45.00High
i
Rating by Gbola Amusa at Chardan Capital
5/9/2020Chardan CapitalReiterated RatingBuy$45.00High
i
Rating by Gbola Amusa at Chardan Capital
3/22/2020Chardan CapitalReiterated RatingBuy$45.00Low
i
Rating by Gbola Amusa at Chardan Capital
3/2/2020Chardan CapitalReiterated RatingBuy$45.00Medium
i
Rating by Gbola Amusa at Chardan Capital
1/30/2020Chardan CapitalReiterated RatingBuy$45.00Medium
i
Rating by Gbola Amusa at Chardan Capital
12/16/2019Piper Jaffray CompaniesReiterated RatingBuy$40.00Low
i
Rating by Tyler Van Buren at Piper Jaffray Companies
12/16/2019Chardan CapitalReiterated RatingBuy$45.00Low
i
9/23/2019Chardan CapitalReiterated RatingBuy$45.00Low
i
9/3/2019Piper Jaffray CompaniesInitiated CoverageOverweight$40.00High
i
5/15/2019BarclaysBoost Price TargetPositive$20.00 ➝ $30.00High
i
5/14/2019Chardan CapitalReiterated RatingBuyHigh
i
2/27/2019Chardan CapitalBoost Price TargetBuy ➝ Buy$30.00 ➝ $40.00High
i
1/31/2019Chardan CapitalReiterated RatingBuy$30.00High
i
Rating by G. Amusa at Chardan Capital
10/16/2018Chardan CapitalReiterated RatingBuy$30.00High
i
Rating by G. Amusa at Chardan Capital
8/23/2018Chardan CapitalInitiated CoverageBuyHigh
i
Rating by G. Amusa at Chardan Capital
7/9/2018Evercore ISIInitiated CoverageOutperform$21.00High
i
7/3/2018Bank of AmericaInitiated CoverageBuyHigh
i
7/3/2018BarclaysInitiated CoverageOverweight$20.00High
i
(Data available from 3/6/2016 forward)
MeiraGTx logo
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was founded in 2015 and is based in New York, New York.
Read More

Today's Range

Now: $14.56
$13.58
$14.71

50 Day Range

MA: $15.52
$13.90
$16.43

52 Week Range

Now: $14.56
$8.82
$18.45

Volume

131,708 shs

Average Volume

113,151 shs

Market Capitalization

$559.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33

Frequently Asked Questions

What sell-side analysts currently cover shares of MeiraGTx?

The following sell-side analysts have issued reports on MeiraGTx in the last year: Bank of America Co., Chardan Capital, Piper Sandler, Royal Bank of Canada, and Zacks Investment Research.
View the latest analyst ratings for MGTX.

What is the current price target for MeiraGTx?

4 Wall Street analysts have set twelve-month price targets for MeiraGTx in the last year. Their average twelve-month price target is $33.00, suggesting a possible upside of 126.6%. Chardan Capital has the highest price target set, predicting MGTX will reach $45.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $20.00 for MeiraGTx in the next year.
View the latest price targets for MGTX.

What is the current consensus analyst rating for MeiraGTx?

MeiraGTx currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MGTX will outperform the market and that investors should add to their positions of MeiraGTx.
View the latest ratings for MGTX.

What other companies compete with MeiraGTx?

How do I contact MeiraGTx's investor relations team?

MeiraGTx's physical mailing address is 450 East 29thStreet 14thFloor, NEW YORK NY, 10016. The company's listed phone number is 646-860-7985 and its investor relations email address is [email protected] The official website for MeiraGTx is www.meiragtx.com.